Skip to main content

Table 4 Severity and ICU management of AKI and outcomes

From: Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis

Variables DAP (N = 28) VAN (N = 44) p
AKI severity and management
 AKI stage 2 or 3, or GFR decrease > 50% 7 (25.0) 25 (56.8) .008
 Maximal variation of GFR except RRT (N = 57), % -6 [−46 to + 13] −31 [−49 to −8] .055
 RRT initiated during treatment, n (%) 2 (7.1) 13 (29.5) .022
 Proportion of ICU days with RRTa, % 0 [0–0] 0 [0–13] .032
Outcomes
 Muscular toxicity (CK > 3xUSL), n (%) 4 (14.3) 0  
 Hypersensitivity manifestation, n (%) 0 1 (2)  
 Length of ICU staya,b (N = 53), days 9 [4–28] 12 [5–25] .827
 Length of in-hospital staya,b (N = 41), days 47 [19–62] 39 [23–52] .543
 28-day mortality (N = 71), n (%) 3 (10.7) 11 (25.6) .124
 180-day mortality (N = 69), n (%) 10 (35.7) 22 (53.7) .142
  1. Quantitative data are expressed as median [interquartile range], except otherwise specified
  2. aAfter study drug initiation
  3. bCensored for inpatient mortality
  4. DAP daptomycin, VAN vancomycin, GFR estimate glomerular filtration rate, RRT renal replacement therapy, AKI acute kidney injury, CK creatine kinase, USL upper superior limit, ICU intensive care unit